Pubdate: Fri, 19 Nov 2004 Source: Vancouver Sun (CN BC) Copyright: 2004 The Vancouver Sun Contact: http://www.canada.com/vancouver/vancouversun/ Details: http://www.mapinc.org/media/477 Author: Jenny Lee Bookmark: http://www.mapinc.org/hr.htm (Harm Reduction) Bookmark: http://www.mapinc.org/find?142 (Safe Injecting Rooms) Bookmark: http://www.mapinc.org/find?137 (Needle Exchange) U.S. DONATES $8 MILLION TO DRUG-USER STUDY The Funds Will Support A Local Health Study On Injection Users, And One On Youth At Risk The U.S. health department will spend more than $3 million over five years to support the Vancouver Injection Drug Users Study and fund a sub-study on youth at risk, the B.C. Centre for Excellence in HIV/AIDS announced Thursday. The Vancouver Injection Drug Users Study (VIDUS) has tracked the lives and the health of drug users in Vancouver since 1996. The area of study includes Vancouver's Downtown Eastside, which has one of the densest populations of injection drug users in North America. "We're now in the position, by adding the youth component to our existing study, to study the natural history of injection drug use from initiation to cessation or death," VIDUS co-principal investigator Thomas Kerr said in an interview. "We can study what helps people avoid starting injection and what helps people stay alive and healthy, and what helps them quit injecting." Vancouver has been at the "leading edge" in injection drug use research for some time, Kerr said. "We have a unique setting. We have a very well set up Centre for Excellence in HIV/AIDS that has a proven track record in conducting research of this kind. We also have a very large HIV epidemic and we have a large, open drug scene. We've been following these people now for a long time." VIDUS is an observational study that follows a defined group of people, or cohort, over time. Large, long-standing studies of injection drug users are hard to come by as they are expensive and complicated to set up. As well, keeping track of participants can be a major challenge. As a result, the VIDUS study which follows more than 1,500 injection drug users, is a "critical source of information about what is a very serious health and social problem in Canada and elsewhere," Kerr said. The Downtown Eastside's density works to Kerr's advantage. "We have a very high follow-up rate with our study," he said. "Participation has been great. Even when they spend time in jail or move to other cities, many still [check in]. We're also very good at finding them." The U.S. government's $612,000 annual grant is awarded by the U.S. Department of Health's National Institutes of Health on a competitive basis for academic merit, Brian Harrigan, B.C. Centre for Excellence in HIV/AIDS director of administration and operations, said in an interview. The sub-study on youth-at-risk will look at the circumstances that lead to injection drug use, the rate at which youth begin injecting and what might help prevent youth from starting to inject, Kerr said. The study will encompass an assessment of the impact of crystal methamphetamine. "This is a serious problem and early indications suggest the problem is getting worse," Kerr said. "There are serious health complications associated with crystal meth use and this study will help us gain a better understanding of the problem and the ways we can address it." An estimated 2,500 street youth live in the Vancouver area. Kerr hopes to begin reporting results on the youth study within 18 months. VIDUS received $1.5 million in funding from the NIH between 1998 and 2001 to study needle exchange in the local HIV epidemic. VIDUS alerted policy makers to the HIV outbreak in 1996, documented the extent and dynamics of the epidemic, evaluated HIV treatment, demonstrated the role of cocaine use as a predictor of HIV infection, and provided data that led to the establishment of Vancouver's safe-injection facility. The funding will help sustain two principal investigators and probably a dozen staff, interviewers and nurses, Harrigan said. The B.C. Centre for Excellence is also evaluating the supervised injection site, and working on another large cohort study for the Vancouver Coastal Health Authority. - --- MAP posted-by: Larry Seguin